# Nuvectis Pharma, Inc.: financial statements, quarterly

NVCT · Nasdaq · CIK 1875558 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nvct.md) · [Financials](/companies/nvct/financials.md) · [Filings](/companies/nvct/filings.md) · [Insiders](/companies/nvct/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nvct/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $k | [4,486](/filings/0001558370-24-014340.md) | [4,265 d](/filings/0001558370-25-001496.md) | [2,660](/filings/0001558370-25-006497.md) | [2,943](/filings/0001558370-25-010203.md) | [2,819](/filings/0001104659-25-105939.md) | [4,496 d](/filings/0001104659-26-013044.md) | [3,680](/filings/0001104659-26-055318.md) | [3,613](/filings/0001104659-26-090109.md) | [5,774](/filings/0001104659-25-105939.md) | [5,086 d](/filings/0001104659-26-013044.md) | [4,106](/filings/0001104659-26-055318.md) | [4,684](/filings/0001104659-26-090109.md) |
| Operating income | $k | [(6,158)](/filings/0001558370-24-014340.md) | [(6,866) d](/filings/0001558370-25-001496.md) | [(4,396)](/filings/0001558370-25-006497.md) | [(4,643)](/filings/0001558370-25-010203.md) | [(4,359)](/filings/0001104659-25-105939.md) | [(6,449) d](/filings/0001104659-26-013044.md) | [(5,568)](/filings/0001104659-26-055318.md) | [(6,595)](/filings/0001104659-26-090109.md) | [(7,794)](/filings/0001104659-25-105939.md) | [(7,617) d](/filings/0001104659-26-013044.md) | [(6,260)](/filings/0001104659-26-055318.md) | [(7,197)](/filings/0001104659-26-090109.md) |
| Net income | $k | [(5,881)](/filings/0001558370-24-014340.md) | [(6,622) d](/filings/0001558370-25-001496.md) | [(4,171)](/filings/0001104659-25-105939.md) | [(4,428)](/filings/0001104659-25-105939.md) | [(4,153)](/filings/0001104659-25-105939.md) | [(6,248) d](/filings/0001104659-26-013044.md) | [(5,332)](/filings/0001104659-26-090109.md) | [(6,334)](/filings/0001104659-26-090109.md) | [(7,462)](/filings/0001104659-25-105939.md) | [(7,314) d](/filings/0001104659-26-013044.md) | [(6,050)](/filings/0001104659-26-090109.md) | [(7,020)](/filings/0001104659-26-090109.md) |
| Diluted EPS | $ per share | [(0.37)](/filings/0001558370-24-014340.md) | not reported | [(0.25)](/filings/0001558370-25-006497.md) | [(0.26)](/filings/0001558370-25-010203.md) | [(0.24)](/filings/0001104659-25-105939.md) | not reported | [(0.27)](/filings/0001104659-26-055318.md) | [(0.30)](/filings/0001104659-26-090109.md) | [(0.44)](/filings/0001104659-25-105939.md) | not reported | [(0.26)](/filings/0001104659-26-055318.md) | [(0.30)](/filings/0001104659-26-090109.md) |
| Basic EPS | $ per share | [(0.37)](/filings/0001558370-24-014340.md) | not reported | [(0.25)](/filings/0001558370-25-006497.md) | [(0.26)](/filings/0001558370-25-010203.md) | [(0.24)](/filings/0001104659-25-105939.md) | not reported | [(0.27)](/filings/0001104659-26-055318.md) | [(0.30)](/filings/0001104659-26-090109.md) | [(0.44)](/filings/0001104659-25-105939.md) | not reported | [(0.26)](/filings/0001104659-26-055318.md) | [(0.30)](/filings/0001104659-26-090109.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [22.1](/filings/0001558370-23-018124.md) | [19.1](/filings/0001558370-25-001496.md) | [19.5](/filings/0001558370-24-007072.md) | [18.1](/filings/0001558370-24-010971.md) | [17.2](/filings/0001558370-24-014340.md) | [18.5](/filings/0001104659-26-013044.md) | [29.9](/filings/0001558370-25-006497.md) | [26.8](/filings/0001558370-25-010203.md) | [35.4](/filings/0001104659-25-105939.md) | [31.6](/filings/0001104659-26-090109.md) | [25.1](/filings/0001104659-26-055318.md) | [22.2](/filings/0001104659-26-090109.md) |
| Current assets | $m | [22.3](/filings/0001558370-23-018124.md) | [19.2](/filings/0001558370-25-001496.md) | [19.7](/filings/0001558370-24-007072.md) | [18.3](/filings/0001558370-24-010971.md) | [17.3](/filings/0001558370-24-014340.md) | [18.6](/filings/0001104659-26-013044.md) | [30.1](/filings/0001558370-25-006497.md) | [27.0](/filings/0001558370-25-010203.md) | [35.6](/filings/0001104659-25-105939.md) | [31.7](/filings/0001104659-26-090109.md) | [25.4](/filings/0001104659-26-055318.md) | [22.4](/filings/0001104659-26-090109.md) |
| Total assets | $m | [22.3](/filings/0001558370-23-018124.md) | [19.2](/filings/0001558370-25-001496.md) | [19.7](/filings/0001558370-24-007072.md) | [18.3](/filings/0001558370-24-010971.md) | [17.3](/filings/0001558370-24-014340.md) | [18.6](/filings/0001104659-26-013044.md) | [30.1](/filings/0001558370-25-006497.md) | [27.0](/filings/0001558370-25-010203.md) | [35.6](/filings/0001104659-25-105939.md) | [31.7](/filings/0001104659-26-090109.md) | [25.4](/filings/0001104659-26-055318.md) | [22.4](/filings/0001104659-26-090109.md) |
| Current liabilities | $m | [5.6](/filings/0001558370-23-018124.md) | [7.0](/filings/0001558370-25-001496.md) | [5.7](/filings/0001558370-24-007072.md) | [5.8](/filings/0001558370-24-010971.md) | [6.3](/filings/0001558370-24-014340.md) | [8.9](/filings/0001104659-26-013044.md) | [9.2](/filings/0001558370-25-006497.md) | [10.1](/filings/0001558370-25-010203.md) | [11.6](/filings/0001104659-25-105939.md) | [13.3](/filings/0001104659-26-090109.md) | [11.2](/filings/0001104659-26-055318.md) | [13.3](/filings/0001104659-26-090109.md) |
| Total liabilities | $m | [5.6](/filings/0001558370-23-018124.md) | [7.0](/filings/0001558370-25-001496.md) | [5.7](/filings/0001558370-24-007072.md) | [5.8](/filings/0001558370-24-010971.md) | [6.3](/filings/0001558370-24-014340.md) | [8.9](/filings/0001104659-26-013044.md) | [9.2](/filings/0001558370-25-006497.md) | [10.1](/filings/0001558370-25-010203.md) | [11.6](/filings/0001104659-25-105939.md) | [13.3](/filings/0001104659-26-090109.md) | [11.2](/filings/0001104659-26-055318.md) | [13.3](/filings/0001104659-26-090109.md) |
| Shareholders' equity | $m | [16.7](/filings/0001558370-24-014340.md) | [12.2](/filings/0001104659-26-013044.md) | [14.0](/filings/0001104659-25-105939.md) | [12.5](/filings/0001104659-25-105939.md) | [11.0](/filings/0001104659-25-105939.md) | [9.7](/filings/0001104659-26-090109.md) | [21.0](/filings/0001104659-26-090109.md) | [16.9](/filings/0001104659-26-090109.md) | [24.0](/filings/0001104659-25-105939.md) | [18.4](/filings/0001104659-26-090109.md) | [14.2](/filings/0001104659-26-090109.md) | [9.1](/filings/0001104659-26-090109.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,244) d](/filings/0001558370-24-014340.md) | [(3,850) d](/filings/0001558370-25-001496.md) | [(4,358)](/filings/0001558370-25-006497.md) | [(3,020) d](/filings/0001558370-25-010203.md) | [(2,404) d](/filings/0001104659-25-105939.md) | [(2,465) d](/filings/0001104659-26-013044.md) | [(4,174)](/filings/0001104659-26-055318.md) | [(3,367) d](/filings/0001104659-26-090109.md) | [(4,494) d](/filings/0001104659-25-105939.md) | [(3,974) d](/filings/0001104659-26-013044.md) | [(6,511)](/filings/0001104659-26-055318.md) | [(4,531) d](/filings/0001104659-26-090109.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [14.1](/filings/0001558370-23-018124.md) | [14.7](/filings/0001558370-24-007072.md) | [15.2](/filings/0001558370-24-010971.md) | [16.1](/filings/0001558370-24-014340.md) | [16.6](/filings/0001558370-25-006497.md) | [16.9](/filings/0001558370-25-010203.md) | [17.2](/filings/0001104659-25-105939.md) | [19.9](/filings/0001104659-26-055318.md) | [21.4](/filings/0001104659-26-090109.md) | [22.7](/filings/0001104659-25-105939.md) | [23.4](/filings/0001104659-26-055318.md) | [23.5](/filings/0001104659-26-090109.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 32,581,533 at 2026-07-31, from the cover of the [10-Q filed 2026-08-04](/filings/0001104659-26-090109.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.